Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > DERM Journey Medical > Key Indicators
DERM Journey Medical
3.860
-0.050-1.28%
Post Mkt Price
3.86000.00%
YOY
Do not show
Hide blank lines
(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31(Q3)2021/09/30
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
-- 41.7522 -61.51% 59.841 -61.51% 59.841 -- -30.0625
Receivable Turnover(T)
-- 2.428 29.25% 2.6843 29.25% 2.6843 -- 1.8697
Inventory Turnover(T)
-- 2.2544 -55.88% 5.6957 -55.88% 5.6957 -- 2.311
Fixed Assets Turnover(T)
-- 1.13K 41.78% 478.2879 41.78% 478.2879 -- 534.5946
Total Asset Rate(T)
-- 0.6262 -18.5% 0.8464 -18.5% 0.8464 -- 0.6663
ROIC
-- -73.437% -371.34% -132.524% -371.34% -132.524% -- --
ROE
-- -110.140% -307.55% -168.125% -307.55% -168.125% -- --
ROA
-- -37.750% -578.72% -58.977% -578.72% -58.977% -- -22.166%
Efficiency Ratios
Profitability Ratios TTM
Gross Margin
-- 51.950% -26.84% 49.181% -26.84% 49.181% -- 54.769%
Operating Margin
-- -35.416% -327.67% -40.138% -327.67% -40.138% -- -21.331%
Net Margin
-- -60.282% -687.37% -69.683% -687.37% -69.683% -- -33.268%
EBITDA Margin
-- -0.4468% -346.73% -0.519% -346.73% -0.519% -- -0.3363%
R & D Expense Ratio
-- 23.540% -- 26.230% -- 26.230% -- 0.000%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-- 35.661% -- -- -- -- -- --
Total Assets to Common Equity
-- 291.764% -54.12% 231.392% -54.12% 231.392% -- --
Debt to Asset Ratio
-- 35.839% -95.88% 2.165% -95.88% 2.165% -- --
Current Ratio
-- 1.4804 30.37% 1.6373 30.37% 1.6373 -- 1.1172
Quick Ratio
-- 1.1893 22.01% 1.3989 22.01% 1.3989 -- 0.8936
GrowthRatios
Growth Ratios
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company’s marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
CEO: --
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top